Phacoemulsification vs SLT as Initial Treatment for Pseudoexfoliation Glaucoma
- Conditions
- Pseudoexfoliation Glaucoma
- Registration Number
- NCT04416724
- Lead Sponsor
- Nova Scotia Health Authority
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> 1. Pseudoexfoliation syndrome, detected at slit-lamp examination by exfoliative<br> material on anterior capsule, pupil, or anterior chamber angle<br><br> 2. Clinical decision to lower the IOP, as assessed by the investigator who is treating<br> the subject, based on the presence of PXG or with IOP elevated enough to warrant<br> treatment, even without clear evidence of optic nerve damage or visual field defect<br><br> 3. Presence of asymptomatic early cataract<br><br>Exclusion Criteria:<br><br> 1. Age less than 50 years old<br><br> 2. Anterior chamber angle closure at gonioscopy, defined as pigmented trabeculum<br> visible in less than 180º<br><br> 3. Previous IOP lowering procedure such as trabeculoplasty, trabeculectomy, or<br> minimally invasive glaucoma surgery<br><br> 4. Previous use of IOP lowering medication for more than 6 months<br><br> 5. Presence of ocular or systemic pathology or medication that could significantly<br> influence the IOP, such as: uveitis, neovascular or traumatic glaucoma, corneal<br> pathology influencing tonometry, use of oral steroids<br><br> 6. IOP at baseline visit higher than 36 mmHg<br><br> 7. Visual field damage at baseline visit with mean deviation worse than -15 dB<br><br> 8. Not able or willing to provide voluntary, informed consent to participate in the<br> study
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Medication-free intraocular pressure control
- Secondary Outcome Measures
Name Time Method Medication-free intraocular pressure control;Intraocular pressure change from baseline;Number of intraocular pressure lowering medications;Time to introduction of intraocular pressure lowering medications;Number of adverse effects;Score at the Glaucoma Quality of Life - 15